Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Institutional Phase II Study of Single Agent Abraxane as Second Line Therapy in Patients With Advanced Transitional Cell Carcinoma of the Urothelium

NCT00683059 is registered in ClinicalTrials.gov with Sunnybrook Health Sciences Centre as lead sponsor.

NCT NCT00683059
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00683059 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Institutional Phase II Study of Single Agent Abraxane as Second Line Therapy in Patients With Advanced Transitional Cell Carcinoma of the Urothelium
Lead sponsor
Sunnybrook Health Sciences Centre
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2008
Completion date
June 30, 2012
Enrollment
48 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

transitional cell carcinoma